58.08
price down icon7.63%   -4.80
after-market Dopo l'orario di chiusura: 58.80 0.72 +1.24%
loading
Precedente Chiudi:
$62.88
Aprire:
$57.91
Volume 24 ore:
32.42M
Relative Volume:
3.66
Capitalizzazione di mercato:
$293.24B
Reddito:
$42.09B
Utile/perdita netta:
$14.65B
Rapporto P/E:
17.69
EPS:
3.2833
Flusso di cassa netto:
$10.11B
1 W Prestazione:
-5.11%
1M Prestazione:
-27.54%
6M Prestazione:
-50.87%
1 anno Prestazione:
-53.36%
Intervallo 1D:
Value
$57.28
$59.06
Intervallo di 1 settimana:
Value
$57.28
$66.75
Portata 52W:
Value
$57.28
$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Nome
Novo Nordisk Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
76,302
Name
Cinguettio
@novonordisk
Name
Prossima data di guadagno
2024-12-06
Name
Ultimi documenti SEC
Name
NVO's Discussions on Twitter

Confronta NVO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
58.08 293.24B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
LLY
Lilly Eli Co
839.96 677.40B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
157.47 371.98B 89.33B 21.81B 18.06B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
172.99 316.82B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.86 216.19B 51.72B 11.94B 13.81B 5.88

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-17 Downgrade BMO Capital Markets Outperform → Market Perform
2025-03-13 Aggiornamento Kepler Hold → Buy
2025-03-03 Downgrade Stifel Buy → Hold
2025-02-12 Iniziato Morgan Stanley Equal-Weight
2025-01-06 Aggiornamento Bernstein Underperform → Mkt Perform
2024-05-30 Iniziato Goldman Buy
2024-04-12 Iniziato BMO Capital Markets Outperform
2024-01-23 Iniziato Morgan Stanley Overweight
2024-01-16 Ripresa UBS Neutral
2023-12-01 Iniziato Cantor Fitzgerald Overweight
2023-10-02 Iniziato Argus Buy
2023-07-14 Iniziato HSBC Securities Buy
2022-07-15 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-06-28 Downgrade UBS Neutral → Sell
2022-06-27 Aggiornamento Exane BNP Paribas Underperform → Neutral
2022-06-07 Aggiornamento JP Morgan Neutral → Overweight
2022-05-31 Aggiornamento Guggenheim Neutral → Buy
2022-04-25 Aggiornamento Cowen Market Perform → Outperform
2022-04-12 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-03-16 Aggiornamento Deutsche Bank Hold → Buy
2022-01-25 Downgrade Liberum Hold → Sell
2021-12-20 Downgrade JP Morgan Overweight → Neutral
2021-12-17 Downgrade Deutsche Bank Buy → Hold
2021-01-20 Downgrade Credit Suisse Outperform → Neutral
2021-01-15 Iniziato Deutsche Bank Buy
2020-09-29 Iniziato Berenberg Hold
2020-07-06 Downgrade BofA Securities Buy → Neutral
2020-05-11 Downgrade UBS Buy → Neutral
2020-05-04 Iniziato Cowen Market Perform
2020-03-16 Aggiornamento BofA/Merrill Neutral → Buy
2020-01-03 Downgrade Guggenheim Buy → Neutral
2019-11-18 Aggiornamento Barclays Equal Weight → Overweight
2019-09-17 Aggiornamento Citigroup Neutral → Buy
2019-08-30 Downgrade Jefferies Hold → Underperform
2019-06-20 Downgrade Deutsche Bank Buy → Hold
2019-06-11 Aggiornamento Barclays Underweight → Equal Weight
2019-04-29 Aggiornamento Credit Suisse Neutral → Outperform
2019-01-29 Iniziato Exane BNP Paribas Outperform
2018-12-11 Ripresa Jefferies Hold
2018-10-09 Iniziato Guggenheim Buy
2017-12-29 Aggiornamento JP Morgan Underweight → Neutral
2017-12-06 Aggiornamento BofA/Merrill Neutral → Buy
2017-12-01 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2017-09-25 Downgrade Exane BNP Paribas Outperform → Neutral
2017-09-06 Aggiornamento BofA/Merrill Underperform → Neutral
Mostra tutto

Novo Nordisk Adr Borsa (NVO) Ultime notizie

pulisher
04:51 AM

Where Will Eli Lilly Be in 5 Years? - The Motley Fool

04:51 AM
pulisher
Apr 09, 2025

Is Novo Nordisk Stock a Buy After its Collapse? - Morningstar

Apr 09, 2025
pulisher
Apr 08, 2025

Eli Lilly and Novo Nordisk: Obesity Drug Coverage in Medicare Not a Straight Path - Morningstar

Apr 08, 2025
pulisher
Mar 28, 2025

Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Why Novo Nordisk Stock Dipped on Thursday - Yahoo Finance

Mar 27, 2025
pulisher
Mar 15, 2025

Novo Nordis Share Price | NYSE: NVO Stock - Investing.com UK

Mar 15, 2025
pulisher
Mar 13, 2025

NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView

Mar 13, 2025
pulisher
Mar 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - Finansavisen

Mar 11, 2025
pulisher
Mar 10, 2025

Novo Nordisk shares plunge after obesity drug trial - The Irish Independent

Mar 10, 2025
pulisher
Mar 07, 2025

Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus.com

Mar 07, 2025
pulisher
Mar 06, 2025

Novo Nordisk A/S Sponsored ADR Class B to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

NVO Stock Quote Price and Forecast - CNN

Mar 06, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

Repare Surprises On Earnings; California Resources Falls Short - Evrim Ağacı

Mar 03, 2025
pulisher
Mar 03, 2025

Why weight-loss drugs are the top target of Medicare price negotiations - Equities News

Mar 03, 2025
pulisher
Feb 19, 2025

Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register

Feb 19, 2025

Novo Nordisk Adr Azioni (NVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$172.99
price up icon 0.76%
drug_manufacturers_general NVS
$110.86
price up icon 1.17%
drug_manufacturers_general JNJ
$157.47
price up icon 2.31%
drug_manufacturers_general MRK
$78.00
price up icon 2.01%
$277.29
price down icon 1.89%
Capitalizzazione:     |  Volume (24 ore):